BlackRock Fund Advisors - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 22 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BlackRock Fund Advisors ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q4 2016$4,000
+100.0%
1,621
+50.0%
0.00%
Q3 2016$2,000
-33.3%
1,081
+15.4%
0.00%
Q2 2016$3,000
-90.0%
937
-91.1%
0.00%
Q1 2016$30,000
-38.8%
10,518
-7.0%
0.00%
Q4 2015$49,000
-40.2%
11,304
+5.4%
0.00%
Q3 2015$82,000
-26.1%
10,726
+7.9%
0.00%
Q2 2015$111,0009,9430.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q4 2015
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 4,758,426$3,340,0002.33%
PERKINS CAPITAL MANAGEMENT INC 2,527,000$1,774,0001.59%
Cowen Prime Services LLC 2,137,900$1,501,0000.69%
HighMark Wealth Management LLC 192,000$134,0000.14%
Nantahala Capital Management 5,000,000$3,510,0000.11%
Kalos Management, Inc. 66,900$48,0000.02%
FNY Investment Advisers, LLC 20,500$14,0000.00%
Virtu Financial LLC 31,991$22,0000.00%
Engineers Gate Manager LP 25,440$18,0000.00%
BlackRock Inc. 405,725$285,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders